Form 4: Akebia Therapeutics CFO Executes Pre-Planned Stock Sale for Tax Obligations

Akebia Therapeutics' SVP, CFO, CBO & Treasurer, Erik Ostrowski, sold 41,314 shares of common stock at $3.67 per share on June 30, 2025, to cover tax withholding obligations related to restricted stock unit vesting under a Rule 10b5-1 plan.

Summary

• Erik Ostrowski, SVP, CFO, CBO & Treasurer of Akebia Therapeutics, Inc. (AKBA), reported a transaction involving the sale of common stock.
• The transaction occurred on June 30, 2025.
• A total of 41,314 shares of common stock were disposed of at a price of $3.67 per share.
• Following this transaction, Erik Ostrowski beneficially owns 503,586 shares of common stock.
• The sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 21, 2024.
• The sale was automatically executed by Akebia Therapeutics to cover tax withholding obligations in connection with the vesting and settlement of one-third of Erik Ostrowski's restricted stock units granted on June 28, 2024.

Sentiment

Score: 5

Explanation: The transaction is a routine, pre-planned sale for tax purposes related to equity compensation, which is a neutral event and does not indicate positive or negative sentiment about the company's performance or future prospects.

Future Outlook

This document, a Form 4, reports an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on June 28, 2024.

Industry Context

This transaction is a routine insider stock sale, specifically for tax withholding purposes related to equity compensation. Such transactions are common across industries for executives receiving restricted stock units or other forms of equity-based compensation, and they typically do not reflect a change in the company's strategic direction or financial health.

Related Party Transactions

• The sale of shares was automatically made by the Issuer (Akebia Therapeutics, Inc.) to cover tax withholding obligations for Erik Ostrowski, a company officer, in connection with the vesting of his restricted stock units.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but this is a routine tax-related sale and not indicative of a change in management's confidence.
• Employees: No direct impact on general employees from this specific transaction.

Key Dates

Keywords

Akebia Therapeutics, AKBA, Form 4, Insider Transaction, Erik Ostrowski, CFO, 10b5-1 Plan, Stock Sale, Restricted Stock Units, Tax Withholding